IN VITRO DIAGNOSTIC TESTING BY PATIENTS AT HOME WILL GROW 27%
IN VITRO DIAGNOSTIC TESTING BY PATIENTS AT HOME WILL GROW 27% per year between now and 1990, Boston Biomedical Consultants President Henry Weinert predicted Aug. 1 at a briefing on the in vitro diagnostic market held at the 36th annual meeting of the American Assn. for Clinical Chemistry in Washington, D.C. In 1983, at-home testing accounted for about 2%, or $56 mil., of a total $2.6 bil. U.S. market for laboratory assays, newly distributed in vitro diagnostics, and DNA probe products, according to Weinert. By 1990, at-home testing will increase to about $294 mil., Weinert noted. Self-testing will be the fastest growing site for in vitro diagnostics, Weinert said, in line with shifting test locations due to cost-containment concerns. Commercial labs will show the slowest market growth, predicted Weinert, at about 6% a year. Hospital lab locations will increase diagnostic testing by about 11% a year between now and 1990; clinics and health maintenance organizations will grow about 19% a year; and the physician's office location will increase 16%, Weinert said. Overall, basic demand for routine in vitro diagnostic tests will be stable at an annual growth rate of 10%, according to the health care consulting firm. That growth rate is driven by an increasing physician, or requestor, population, Weinert explained. In 1982, there were a total of 440,000 physicians in practice in the U.S., he said. By 1990, that number will climb 2.4% to 530,000. In 1983, the U.S. testing volume was 6.7 bil. tests, Boston Biomedical's Ruth Emyanitoff, PhD, stated at the briefing. Hospitals performed 4 bil. of those tests, commercial labs accounted for 2 bil., outpatient facilities and physician's office each performed 280 mil., and patients at home performed about 140 mil. tests, she said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth